TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Special Drug Use Surveillance of Vonoprazan for Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs: Long-term Use

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~- Participants with a history of gastric or duodenal ulcer~Exclusion Criteria:~* Participants with gastric or duodenal ulcer at initiation of vonoprazan therapy~* Participants with active upper gastrointestinal haemorrhage at initiation of vonoprazan therapy~* Participants with a history of hypersensitivity to any ingredients of vonoprazan Tablets~* Participants receiving atazanavir sulfate or rilpivirine hydrochloride

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vonoprazan 10 mg (Type: None): The usual adult dosage for oral use is 10 mg of Vonoprazan administered once daily. Participants will receive interventions as part of routine medical care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pen-Administered Low-Dose Dasiglucagon for Prevention and Treatment of Hypoglycemia in People With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* T1D ≥ 2 years~* Use of insulin pump therapy (without sensor-augmented insulin suspension/adjustment functionality) ≥ 6 months~* Use of CGM (real-time or intermittently scanned) ≥ 3 months and ≥ 70% during the previous 14 days~* HbA1c ≤ 70 mmol/l (8.5%)~* Performs aerobic exercise on a regular basis (≥ 2 times per week; self-reported) and desires to exercise per American Diabetes Association guidelines (150 minutes per week) during the study.~* Use of carbohydrate counting and bolus calculator (self-reported)~* Sensor glucose level \< 3.9 mmol/l on ≥ 4/14 previous days assessed by CGM data~Exclusion Criteria:~* Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period and within 30 days prior to study start~* Known or suspected allergies to glucagon or related products~* History of hypersensitivity or allergic reaction to dasiglucagon or any of the excipients~* Patients with pheochromocytoma or insulinoma~* Hypoglycemia unawareness~* Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods~* Inability to understand the individual information and to give informed consent~* Current participation in another clinical trial that, in the judgment of the investigator, will compromise the results of the study or the safety of the subject~* Concomitant medical or psychological conditions identified through review of medical history, physical examination and clinical laboratory analysis that, according to the investigator's assessment, makes the individual unsuitable for study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Usual care (Type: NO_INTERVENTION): During the 'usual care' period, participants will manage episodes of manifest or impending hypoglycemia as usual, e.g. through carbohydrate consumption or manual insulin pump suspension.
- Dasiglucagon (Type: EXPERIMENTAL): During the 'dasiglucagon' period, participants will use pen-administered low-dose (80 µg) dasiglucagon to treat or prevent episodes of hypoglycemia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic Response

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index within the range 18.5-35.0 kilograms/metre2 (kg/m2).~* Females of non-child bearing potential.~* Documented history of bronchial asthma, first diagnosed at least 6 months prior to the screening visit and currently being treated only with intermittent short-acting beta -agonist therapy by inhalation~* Pre-bronchodilator FEV1 \>70% of predicted at screening~* Subjects who are current non-smokers~* Methacholine challenge PC20 \< 8 mg/mL at screening~* Screening allergen challenge demonstrates that the subject experiences an early asthmatic response~Exclusion Criteria:~* Current or chronic history of liver disease, or known hepatic or biliary abnormalities~* Subject is hypertensive at screening~* Respiratory tract infection and/or exacerbation of asthma within 4 weeks prior to the first dose of study medication.~* History of life-threatening asthma~* Symptomatic with hay fever at screening or predicted to have symptomatic hayfever~* Unable to abstain from short acting beta agonists~* Unable to abstain from antihistamines~* Unable to abstain from other medications including non-steroidal anti-inflammatory drugs (NSAIDs), anti-depressant drugs, anti-asthma anti-rhinitis or hay fever medication~* The subject has participated in a study with a new molecular entity during the previous 3 months or has participated in 4 or more clinical studies in the previous 12 months~* undergoing allergen desensitisation therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Inhaler
- inhaled corticosteroid(ICS)/long acting bronchodilator (LABA) (Type: ACTIVE_COMPARATOR): ICS/LABA inhaler
- ICS (Type: ACTIVE_COMPARATOR): ICS inhaler

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Postpartum Weight Loss for Women at Elevated Cardiovascular Risk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥18 years;~2. Delivered a baby at HUP or PAH within 3-12 months prior to study start;~3. BMI ≥ 27 kg/m2~4. Diagnosis of one of the following medical conditions: chronic hypertension, gestational hypertension, preeclampsia, eclampsia, gestational diabetes, or diabetes mellitus (type 1 or 2) based on diagnosis codes in the EMR~5. Has online access through smartphone or computer and has email address~6. Ability to read and provide informed consent to participate in the study~Exclusion Criteria:~1. Delivered prior to 32 weeks gestation in the EMR~2. Documentation of fetal demise or neonatal demise in the EMR~3. Currently pregnant or planning to get pregnant within the next 5 months~4. Does not speak English~5. Answers yes to any of the following questions:~   * Are you currently participating in any other weight loss or physical activity studies?~  * Do you have any medical conditions or other reasons why you could not participate in a 16-week weight loss or physical activity program?~6. Participants will be excluded after completing the run-in period if they do not complete the daily food log or their baseline BMI is \< 27 kg/m2

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Online Behavioral Weight Loss (Type: ACTIVE_COMPARATOR): Participants will attend a virtual introduction to weight loss session and be enrolled in a 16-week online behavioral weight loss program. Participants will complete a virtual weigh-in at the start and end of the study.
- Usual Care (Type: ACTIVE_COMPARATOR): Participants will complete a virtual weigh-in at the start and end of the study. No additional intervention will be provided.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of ADHD according to the Diagnostic and Statistical Manual of Mental Diseases, Fourth Edition (DSM-IV) and confirmed by the Conners' Adult ADHD Diagnostic Interview for DSM IV~* Described chronic course of ADHD symptomatology from childhood to adulthood, with some symptoms present before age 7 years and continue to meet DSM-IV criteria at the time of assessment~* CAARS score of at least or equal to 24 as determined by investigator at screening visit~* Patient agrees to take only the supplied study drug as treatment for ADHD during the study~* Patient agrees not to initiate a new behavioral modification program during the study or if currently using a behavioral modification program agrees not to change this program during the study.~Exclusion Criteria:~* Known to be a non-responder to methylphenidate, or patient has a child known to be a non-responder to methylphenidate~* Has been treated with any methylphenidate-containing medication within 1 month of screening visit~* Participation in and premature withdrawal from 42603ATT3002, CR002479 or 42603ATT3004, CR011068 study~* Known allergy or hypersensitivity to methylphenidate, or components of PR OROS methylphenidate~* Any clinically unstable psychiatric condition including, but not limited to the following: acute mood disorder, bipolar disorder, acute obsessive-compulsive disorder (OCD), anti-social personality disorder, borderline personality disorder.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): prolonged release (PR) OROS methylphenidate 54 mg 18+36mg once daily for 13 weeks
- 002 (Type: EXPERIMENTAL): prolonged release (PR) OROS methylphenidate 72 mg 2x36mg once daily for 13 weeks
- 003 (Type: PLACEBO_COMPARATOR): Placebo 2xplacebo once daily for 13 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Body mass index (BMI) ≤ 45 kg/m2~2. Fasting Triglycerides (TG) ≥ 500 mg/dL (≥ 5.7 mmol/L) at Screening.~3. If on statin or fibrate, participants must be on stable, labeled dose for at least 3 months prior to screening. Participants not receiving these drugs within 4 weeks prior to screening are also eligible.~Exclusion Criteria:~1. Type 1 diabetes mellitus~2. Newly diagnosed type 2 diabetes mellitus (within 12 weeks of screening) or HbA1c ≥ 9.0% at Screening~3. Acute pancreatitis within 3 months of screening~4. Acute Coronary Syndrome within 6 months of screening~5. Major surgery within 3 months of screening~6. Prior exposure to ISIS 304801~7. Have any other conditions in the opinion of the investigator which could interfere with the participant participating in or completing the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Volanesorsen-matching placebo administered subcutaneously once-weekly for 26 weeks.
- Volanesorsen 300 mg weekly (Type: EXPERIMENTAL): Volanesorsen 300 mg administered subcutaneously once-weekly for 26 weeks.
- Volanesorsen 300 mg biweekly, post Week 13 (Type: EXPERIMENTAL): Volanesorsen 300 mg administered subcutaneously once-weekly for 13 weeks, then bi-weekly for 13 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Low Sodium Intake on the Anti-proteinuric Efficacy in Hypertensive Patient With Olmesartan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 19 years or more and 75 years or less~* Hypertension patients: Patients whose blood pressure is 140/90mmHg and over, patients is newly diagnosed with hypertension or is prescribed antihypertensive medications.~* Hypertensive patients verified 2 times or more of albuminuria 30 mg/g cr or more in a spot urine sample with interval of 1 week or more in recent 6 months~* Estimated glomerular filtration rate (GFR) by Modification of Diet in Renal Disease (MDRD) equation 30 ml/min/1.73 m2 or more~* Patients who give written consent to this study by oneself~Exclusion Criteria:~* Blood pressure more than 160/100 mmHg~* Pregnant~* Serum potassium level more than 5.5 mEq/L at screening period~* Patients with malignancy, acute cerebral infarction, acute myocardial infarction, unstable angina, percutaneous coronary arterial intervention (PCI), or coronary artery bypass graft (CABG) in recent 6 months~* Patients with diabetes mellitus~* Patients who have an allergy to Olmesartan~* Patients who were involved in other clinical trial in recent 1 month or are participated in screening period~* Patients taking medication(s) of corticosteroid or immunosuppressant in a screening period

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Intensive education of low salt diet (Type: EXPERIMENTAL): For 8 weeks, dietitian will call patients to take the information according to pre-defined questionnaire, to check the daily diet habit and daily food taken, and to guide how to lessen sodium intake for 30 min at each call. The call will be done once a week for 8 weeks. (\*Intervention in this trial is the intensity of education)
- Conventional diet group (Type: NO_INTERVENTION): Education for low salt diet will be conducted as in office with brief communication with a patient and a physician.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Predicting the Response to Montelukast by Genetic Variation in Asthmatics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects, age 18-55~* Clinical history consistent with asthma~* Mild to moderate asthma as determined by pulmonary function tests--60% or higher of predicted FEV1 for age, sex and race.~* Response to hypertonic saline, which will be the main outcome variable measured.~Exclusion Criteria:~* Smokers (total lifetime smoking history\>10 pack-years, any in the past year)~* Pregnant woman-if of childbearing age, not using an acceptable form of birth control.~* Use of a leukotriene modifier within the past month~* Use of inhaled or oral steroids within the past month.~* Emergency room visit for asthma exacerbation within the past 6 weeks.~* Intubation for asthma exacerbation in the past 10 years.~* Adverse reaction to inhaled beta-agonists in the past.~* No recent (past 48 hours) use of anticholinergics, theophylline, antihistamines, pseudoephedrine.~* Patients will also be asked not to use any short acting beta-agonists for 6 hours and long-acting beta-agonists for 48 hours before their initial visit (when pulmonary function evaluation will be performed).~* Lung disease other than asthma~* Significant medical illness other than asthma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study on Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Body Mass Index (BMI) \>=30 and \<50~* BMI \>= 27 and \< 50 if patient has controlled hypertension or abnormal blood lipids~* Stable weight~* Female patients must be postmenopausal for at least 1 year, surgically incapable of childbearing, practicing abstinence, or practicing an acceptable method of contraception (requires negative pregnancy test)~Exclusion Criteria:~* Known contraindication, or hypersensitivity to topiramate~* Exposure to any other experimental drug or device within last 30 days~* A diagnosis of diabetes~* History or evidence of clinically significant liver disease, cardiovascular disease, uncontrolled hypertension or high thyroid levels~* History of obesity with known cause~* History or family history of kidney stones~* History of weight loss surgery~* History of malignancy within last 5 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* IRSS stage II or stage IIIa RB patients.~* for patients with IRSS stage II disease, if scleral surface invasion alone was observed, only systemic chemotherapy was administered, whereas other IRSS stage II and IIIa patients received systemic chemotherapy plus additional local chemotherapy.~* no tumor-related treatment was given prior to this chemotherapy regimen.~Exclusion Criteria:~* metastasis, including lymph node metastasis.~* the diagnosis of IRSS stage I or above in the non-target eye.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CEV with/without carboplatin (Type: EXPERIMENTAL): CEV chemotherapy(CEV Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months) together with/without 20mg/2ml carboplatin periocular injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pts have histologically confirmed diagnosis of recurrent/progressive WHO gr III \& IV MG \& meet following inclusion criteria:~* Age \>18 yrs~* Interval of \>4 wks since prior surgery~* Interval of \>4 wks since prior external beam radiation therapy (XRT) or chemo, unless there is unequivocal evidence of progressive disease \& pts have recovered from all anticipated toxicity of most recent therapy~* Karnofsky performance status score \>60~* Hematocrit \> 29 percent, absolute neutrophil count (ANC) \>1,500 cells/microliter, platelets \>100,000 cells/microliter~* Serum creatinine \<.5mg/dl, blood urea nitrogen (BUN) \<25 mg/dl, serum glutamate oxaloacetate transaminase (SGOT) \& bilirubin \<1.5 x upper limit of normal (ULN)~* For pts on corticosteroids, they have been on stable dose for 1 wk prior to entry~* Pts have had prior bevacizumab are eligible however interval of \>6 wks must have elapsed since their last dose~* Signed informed consent approved by Institutional Review Board (IRB) prior to patient entry;~* If sexually active, pts must agree to take contraceptive measures for duration of treatments~Exclusion Criteria:~* Prior therapy w either bevacizumab/EGFR-directed agents~* \>3 prior recurrences~* Pregnancy/breast feeding~* Co-medication w immuno-suppressive agents other than corticosteroids including but not limited to cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil~* Evidence of central nervous system (CNS) hemorrhage on baseline MRI on CT scan~* Pts who require therapeutic anti-coagulation~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring IV antibiotics \& psychiatric illness/social situations that would limit compliance w study requirements, or disorders associated w significant immunocompromised state~* Pts w another primary malignancy that has required treatment within past year~* Pts w acute/chronic renal insufficiency/those w acute renal insufficiency of any severity due to hepato-renal syndrome/in peri-operative liver transplantation period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab + Erlotinib (Type: EXPERIMENTAL): Bevacizumab + Erlotinib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Generally healthy, postmenopausal women aged 40 - 75 years inclusive~* Intact uterus~* Last natural menstrual cycle (without exogenous hormone therapy) completed at least 12 consecutive months before screening~Exclusion Criteria:~* A history or active presence of thrombophlebitis, thrombosis or thromboembolic disorders~* A history or active presence of cerebrovascular accident, stroke, or transient ischemic attack~* A history or active presence of malignancy, or treatment for malignancy, within the previous 10 years~Additional criteria applies.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: ACTIVE_COMPARATOR): None
- C (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete